Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Metabasis Therapeutics Inc (MBRX) since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data at Metabasis Therapeutics Inc. Table 2 shows the detailed insider transactions. The reporting company's CIK number is 1053221.
Total stock buying since 2005: $24,858,897.
Total stock sales since 2005: $428,418.
Total stock option exercises since 2005: $22,019.
▪ Recent SEC 13D filings for all companies
▪ Funds & ETFs holding MBRX
▪ Recent portfolio reports of all companies
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2008 | 2,337,997 | $5,460,525 | 0 | $0 | 0 | $0 |
| 2007 | 0 | $0 | 33,335 | $268,238 | 0 | $0 |
| 2006 | 577,000 | $4,177,472 | 20,000 | $160,180 | 11,864 | $22,019 |
| 2005 | 2,598,857 | $15,220,900 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2008-11 | 6,000 | $3,654 | 0 | $0 | 0 | $0 |
| 2008-04 | 2,331,997 | $5,456,871 | 0 | $0 | 0 | $0 |
| 2007-06 | 0 | $0 | 13,435 | $107,706 | 0 | $0 |
| 2007-05 | 0 | $0 | 300 | $2,400 | 0 | $0 |
| 2007-04 | 0 | $0 | 15,600 | $126,132 | 0 | $0 |
| 2007-02 | 0 | $0 | 4,000 | $32,000 | 0 | $0 |
| 2006-12 | 0 | $0 | 9,000 | $72,000 | 0 | $0 |
| 2006-11 | 527,000 | $3,775,955 | 9,500 | $76,005 | 0 | $0 |
| 2006-06 | 0 | $0 | 500 | $4,175 | 11,864 | $22,019 |
| 2006-05 | 50,000 | $401,517 | 0 | $0 | 0 | $0 |
| 2006-03 | 0 | $0 | 1,000 | $8,000 | 0 | $0 |
| 2005-09 | 2,598,857 | $15,220,900 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2008-11-19 | Laikind Paul K (Chief Executive Officer) | Buy | 4,700 | .63 | 2,956 |
| 2008-11-18 | Laikind Paul K (Chief Executive Officer) | Buy | 1,300 | .54 | 698 |
| 2008-04-16 | Rosch Thomas L (10% Owner) | Buy | 990,816 | 2.34 | 2,318,509 |
| 2008-04-16 | Galakatos Nicholas (10% Owner) | Buy | 71,866 | 2.34 | 168,166 |
| 2008-04-16 | Oronsky Arnold L (Director) | Buy | 990,816 | 2.34 | 2,318,509 |
| 2008-04-16 | Evnin Luke (Director) | Buy | 71,866 | 2.34 | 168,166 |
| 2008-04-16 | Hale David F | Buy | 10,000 | 2.34 | 23,400 |
| 2008-04-16 | Credit Suisse/ (10% Owner) | Buy | 196,633 | 2.34 | 460,121 |
| 2007-06-19 | Beck John W (Chief Financial Officer) | Sale | 3,400 | 8.05 | 27,376 |
| 2007-06-01 | Beck John W (Chief Financial Officer) | Sale | 10,035 | 8.01 | 80,330 |
| 2007-05-22 | Beck John W (Chief Financial Officer) | Sale | 300 | 8.00 | 2,400 |
| 2007-04-25 | Beck John W (Chief Financial Officer) | Sale | 3,300 | 8.13 | 26,829 |
| 2007-04-24 | Baracchini Edgardo Jr (Sr. VP of Business Development) | Sale | 4,300 | 8.21 | 35,303 |
| 2007-04-10 | Beck John W (Chief Financial Officer) | Sale | 6,172 | 8.00 | 49,376 |
| 2007-04-09 | Beck John W (Chief Financial Officer) | Sale | 1,828 | 8.00 | 14,624 |
| 2007-02-26 | Beck John W (Chief Financial Officer) | Sale | 3,300 | 8.00 | 26,400 |
| 2007-02-26 | Baracchini Edgardo Jr (Sr. VP of Business Development) | Sale | 700 | 8.00 | 5,600 |
| 2006-12-05 | Beck John W (Chief Financial Officer) | Sale | 9,000 | 8.00 | 72,000 |
| 2006-11-27 | Beck John W (CFO) | Sale | 500 | 8.01 | 4,005 |
| 2006-11-08 | Beck John W (Sr. VP, Finance & CFO) | Sale | 9,000 | 8.00 | 72,000 |
| 2006-11-03 | Credit Suisse/ (10% Owner) | Buy | 527,000 | 7.17 | 3,775,955 |
| 2006-06-26 | Baracchini Edgardo Jr (Sr. VP, Business Development) | Sale | 500 | 8.35 | 4,175 |
| 2006-06-07 | Gschwend Heinz W (Director) | Option Ex | 11,864 | 1.86 | 22,019 |
| 2006-05-22 | Cash Harvey B (10% Owner) | Buy | 39,836 | 8.02 | 319,644 |
| 2006-05-19 | Cash Harvey B (10% Owner) | Buy | 5,000 | 8.10 | 40,500 |
| 2006-05-18 | Cash Harvey B (10% Owner) | Buy | 700 | 8.10 | 5,670 |
| 2006-05-16 | Cash Harvey B (10% Owner) | Buy | 4,464 | 8.00 | 35,703 |
| 2006-03-01 | Beck John W (Chief Financial Officer) | Sale | 1,000 | 8.00 | 8,000 |
| 2005-09-30 | Rosch Thomas L (10% Owner) | Buy | 426,621 | 5.86 | 2,499,999 |
| 2005-09-30 | Galakatos Nicholas (Director) | Buy | 699,659 | 5.86 | 4,100,001 |
| 2005-09-30 | Oronsky Arnold L (Director) | Buy | 426,621 | 5.86 | 2,499,999 |
| 2005-09-30 | Evnin Luke (10% Owner) | Buy | 699,659 | 5.86 | 4,100,001 |
| 2005-09-30 | Credit Suisse First Boston/ (Other) | Buy | 341,297 | 5.86 | 2,000,000 |
| 2005-09-07 | Gschwend Heinz W (Director) | Buy | 5,000 | 4.18 | 20,900 |
Insider trading activities including stock purchases, stock sales, and option exercises of MBRX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Metabasis Therapeutics Inc (symbol MBRX, CIK number 1053221) see the Securities and Exchange Commission (SEC) website.